KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.00
+0.00%Margins
Gross margin
91.7%
EBITDA margin
-204.6%
EBIT margin
-233.4%
Net margin
-223.2%
FCF margin
-113.2%
6060.0%
Return on equity
-49.0%
Return on assets
-61.0%
Return on invested capital
0.22x
Asset turnover
-$81.6M
Cash from operations
$5.64
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026